Andrew Hindman
Director/Board Member at BIOTIE THERAPIES CORP
Net worth: 4 M $ as of 2024-04-29
Andrew Hindman active positions
| Companies | Position | Start | End |
|---|---|---|---|
| BIOTIE THERAPIES CORP | Director/Board Member | 2016-11-30 | - |
Career history of Andrew Hindman
Former positions of Andrew Hindman
| Companies | Position | Start | End |
|---|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Director of Finance/CFO | 2019-06-03 | 2022-12-30 |
| ACORDA THERAPEUTICS, INC. | Corporate Officer/Principal | 2016-10-03 | 2019-05-30 |
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director/Board Member | 2011-04-04 | 2013-12-31 |
| Chief Executive Officer | 2011-04-05 | 2013-12-31 | |
| President | 2011-04-05 | 2013-12-31 | |
Nodality, Inc.
 Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 2010-04-30 | 2010-12-31 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 1997-12-31 | 2007-12-31 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 2008-07-31 | - |
| Head of Private Banking | 2008-07-31 | 2011-01-03 |
Training of Andrew Hindman
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Wesleyan University | Undergraduate Degree |
| Haas School of Business | Masters Business Admin |
Statistics
International
| United States | 10 |
| Finland | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Masters Business Admin | 2 |
| Director/Board Member | 2 |
Sectoral
| Health Technology | 8 |
| Consumer Services | 4 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| ACORDA THERAPEUTICS, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| THERAVANCE BIOPHARMA, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Nodality, Inc.
Nodality, Inc. BiotechnologyHealth Technology Nodality, Inc. develops bioinformatics tools to enhance drug development process. Its technology profiles signaling networks in single cells by multiparametric phospho-flow cytometry. The company was founded by Michael C. Needels, Omar D. Perez, Garry P. Nolan and Rodney Weldon Turner in 2003 and is headquartered in San Francisco, CA. | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Biotie Therapies Oy
 Biotie Therapies Oy Pharmaceuticals: MajorHealth Technology Biotie Therapies Oy engages in the research, development, and commercialization of pharmaceutical products. The company was founded by Markku Tapani Jalkanen and Sirpa Tuulikki Jalkanen in June 1992 and is headquartered in Helsinki, Finland. | Health Technology |
- Stock Market
- Insiders
- Andrew Hindman
- Experience
